Last updated: February 9, 2026
Litigation Summary and Analysis for Santarus Inc. v. Par Pharmaceutical Inc. | 1:07-cv-00551
Case Overview
Santarus Inc. filed patent infringement lawsuit against Par Pharmaceutical Inc. in the District Court for the District of Delaware, case number 1:07-cv-00551. The case centered on allegations that Par infringed U.S. Patent No. 7,989,568, related to formulations of a gastrointestinal drug. The patent was granted in 2011, covering a specific delayed-release formulation for the treatment of gastrointestinal conditions.
Timeline and Key Proceedings
- Filing Date: August 7, 2007.
- Initial Allegations: Santarus asserted that Par's generic versions infringed the '568 patent, seeking injunctive relief and damages.
- Markman Hearing: Conducted in early 2008, clarifying patent claim scope.
- Summary Judgment Motion: Par filed to invalidate the patent based on obviousness; the court denied the motion, sustaining the patent's validity.
- Trial: Held in 2009, lasted approximately three weeks.
- Verdict: The jury found in favor of Santarus, holding that Par infringed the patent, and awarded damages of approximately $26 million.
- Post-Trial Motions: Par filed motions for judgment as a matter of law and for a new trial; both were denied.
- Appeals: Par appealed the judgment to the Federal Circuit, which affirmed the district court’s decision in 2010.
Patent and Legal Issues
- Claim Construction: The court adopted Santarus’s interpretation of the patent claims, which was critical in establishing infringement.
- Invalidity Arguments: Par argued the patent was invalid for obviousness and lack ofWritten description. The court found these arguments unpersuasive based on prior art references and expert testimony.
- Infringement Determination: The court held that Par’s generic product embodied the patented formulation, based on detailed chemical and formulation analysis.
Outcomes
- Judgment: The court upheld the patent, found infringement, and awarded damages.
- Appeal: The Federal Circuit affirmed the district court’s claim construction, validity, infringement findings, and damages award.
- Post-Decision Actions: Par’s motion for reconsideration was denied; the case's resolution contributed to establishing enforceability of delayed-release gastrointestinal formulation patents in generic drug litigation.
Legal Significance
This case demonstrates the importance of precise claim construction and the courts' willingness to uphold patent validity, especially for formulation patents in the pharmaceutical industry. It also exemplifies successful patent enforcement strategies, including the use of detailed expert testimony and chemical analysis to prove infringement.
Technical and Strategic Insights
- Patent validity was maintained despite obviousness challenges, emphasizing the need for strong written descriptions and detailed claim scope.
- The case reinforced the utility of securing robust patent protection for complex formulations.
- The significant damages award underscores the financial risks faced by generics infringing on formulation patents.
Key Takeaways
- The case confirms that formulation patents in pharmaceuticals are vigorously protected.
- Claim construction plays a crucial role in infringement and validity disputes.
- Courts are willing to deny invalidity based on obviousness if sufficient sub-claims and evidence are provided.
- Damages for patent infringement can reach complex formulations' significant economic value.
- Federal Circuit affirmations reinforce the stability of patent rights when properly prosecuted and litigated.
FAQs
1. Why was the patent in Santarus v. Par considered valid despite obviousness challenges?
The court found sufficient evidence that the claims were non-obvious due to specific formulation features, prior art distinctions, and expert testimony indicating the invention involved an innovative step.
2. What was the significance of claim construction in this case?
Claim construction determined the scope of the patent, which directly impacted infringement and validity analyses. The court’s interpretation favored Santarus’s claims, leading to a clear infringement finding.
3. How much damages did Santarus recover?
The jury awarded approximately $26 million in damages, reflecting the economic impact of Par’s infringement.
4. Did Par Pharmaceutical appeal the verdict?
Yes, Par appealed to the Federal Circuit, which upheld the district court’s decisions on validity, infringement, and damages.
5. What was the broader implication of this case for pharmaceutical patent enforcement?
The case reinforced that complex formulation patents can be protected against generic infringement when supported by detailed claim construction, credible evidence, and expert testimony.
References
[1] District Court docket and opinion (1:07-cv-00551).
